Drug Induces Morphologic, Molecular and Clinical Remissions in Myelofibrosis
Embargo expired: 12/9/2013 5:45 PM EST
Source Newsroom: Mayo Clinic
MULTIMEDIA ALERT: Video interview is available for journalists on the Mayo Clinic News Network.
Newswise — ROCHESTER, Minn. -- Imetelstat, a novel telomerase inhibiting drug, has been found to induce morphologic, molecular and clinical remissions in some patients with myelofibrosis a Mayo Clinic study has found. The results were presented today at the 2013 American Society of Hematology Annual Meeting in New Orleans.
“These are early results but they are promising, says the study’s lead author, Ayalew Tefferi, M.D. a hematologist at Mayo Clinic. “Some patients in our clinical trial taking imetelstat obtained dramatic responses and there have been some complete responses which is almost unheard of for drug therapy in this disease.”
Myelofibrosis is a chronic myeloid cancer in which bone marrow cells that produce blood cells develop and function abnormally. The result is the formation of scar tissue in the bone marrow (fibrosis), severe anemia that often requires transfusion, weakness, fatigue and an enlarged spleen and liver. Patients with myelofibrosis harbor one of several genetic mutations in their blood stem cells, including JAK2, MPL, CALR, ASXL1 and spliceosome pathway mutations.
“Typically, myelofibrosis is characterized by marrow scarring and although patients may derive symptomatic relief from other treatments such as ruxolitinib, they usually do not revert back to normal bone marrow,” Dr. Tefferi says. “Some patients in our trial have reverted back to normal bone marrow.”
Imetelstat works by inhibiting telomerase activity in tumor cells which leads to cell death.
Researchers studied imetelstat in 33 patients at Mayo Clinic and have now followed the first 22 patients for a minimum of six months. Among the 22, five patients achieved complete or partial remissions, including reversal of bone marrow fibrosis in four of the five patients. Two of the five patients with complete or partial remission have also experienced complete molecular remissions. The overall response rate was 41 percent.
Co-authors include Kebede Begna, M.D., Rebecca Laborde, Ph.D., Mrinal Patnaik, M.B.B.S., Curtis Hanson, M.D., Animesh Pardanani, M.B.B.S., Ph.D., Terra Lasho, Darci Zblewski, Christy Finke, Lauren Schimek, and Betsy LaPlant, all of Mayo Clinic and Monic Stuart, M.D., M.P.H. of Geron Corporation.
Financial support for the study was provided by Geron Corporation.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
# # #
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.com and www.mayoclinic.org/news.
Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded.